Compositions and methods for drug sensitization of parasites

US10226455B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10226455-B2
Application numberUS-201615240270-A
CountryUS
Kind codeB2
Filing dateAug 18, 2016
Priority dateFeb 19, 2014
Publication dateMar 12, 2019
Grant dateMar 12, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof in an amount and formulation sufficient to inhibit or induce drug-sensitization in a parasite. The methods can comprise administering a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof to a parasite in an amount and formulation sufficient to inhibit or induce drug-sensitization in the parasite.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method of sensitizing a parasite to an antiparasitic drug comprising administering a composition having the following formula: wherein R comprises one of the following structures: to the parasite that expresses a P-glycoprotein pump in an amount and for a time sufficient to sensitize the parasite to the antiparasitic drug by inhibiting the P-glycoprotein pump in the parasite and thereby reducing efflux of the antiparasitic drug from the parasite, wherein the antiparasitic drug is a macrocyclic lactone or a quinoline. 2. The method of claim 1 , further comprising administering the composition to the parasite before administering the antiparasitic drug. 3. The method of claim 1 , further comprising administering the composition to the parasite concurrently with the antiparasitic drug. 4. The method of claim 1 , further comprising administering the composition to the parasite after administering the antiparasitic drug. 5. The method of claim 1 , further comprising administering the composition to the parasite a second or greater time. 6. The method of claim 1 , wherein administering the composition to the parasite in an amount and for a time sufficient to sensitize the parasite to the antiparasitic drug comprises rendering the parasite susceptible to the antiparasitic drug at a lower dose than in the absence of the composition. 7. The method of claim 1 , wherein administering the composition to the parasite in an amount and for a time sufficient to sensitize the parasite to the antiparasitic drug comprises rendering the parasite susceptible to the antiparasitic drug that the parasite would not be susceptible to in the absence of the composition. 8. The method of claim 1 , wherein administering the composition to the parasite in an amount and for a time sufficient to sensitize the parasite to the antiparasitic drug comprises rendering the parasite susceptible to death or a decrease in growth due to the antiparasitic drug. 9. The method of claim 1 , wherein the parasite is a species of the genus Plasmodium or a species of the genus Haemonchus. 10. The method of claim 1 , wherein the parasite is Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale , or Plasmodium malariea. 11. The method of claim 1 , wherein the composition is 4-deoxy-3,4[2-spiro-[1-(t-butyloxycarbonyl)-piperidin-4-yl]]-(1H)-imidazo-(2,5-dihydro)rifamycin S, 4-deoxy-3,4[2-spiro-[1-ethyloxycarbonyl)-piperidin-4-yl]]-(1H)-imidazo-(2,5-dihydro)rifamycin S, 4-deoxy-3,4 [2-spiro-[1-(n-propyloxycarbonyl)-piperidin-4-yl]]-(1H)-imidazo-(2,5-dihydro)rifamycin S, 4-deoxy-3,4[2-spiro-[1-(isobutyloxycarbonyl)-piperidin-4-yl]]-(1H)-imidazo-(2,5-dihydro)rifamycin S, 4-deoxy-3,4[2-spiro-[1-(benzyloxycarbonyl)-piperidin-4-yl]]-(1H)-imidazo-(2,5-dihydro)rifamycin S, 4-deoxy-3,4[2-spiro-[1-(ethylaminocarbonyl)-piperidin-4-yl]]-(1H)-imidazo-(2,5-dihydro)rifamycin S, 4-deoxy-3,4[2-spiro-[1-(isopropyloxycarbonyl)-piperidin-4-yl]]-(1H)-imidazo-(2,5-dihydro)rifamycin S, 4-deoxy-3,4[2-spiro-[1-(phenylaminocarbonyl)-piperidin-4-yl]]-(1H)-imidazo-(2,5-dihydro)rifamycin S, 4-deoxy-3,4[2-spiro-[1-(acetyl)-piperidin-4-yl]]-(1H)-imidazo-(2,5-dihydro)rifamycin S, 4-deoxy-3,4[2-spiro-[1-(beRTIoyl)-piperdin-4-yl]]-(1H)-imidazo-(2,5-dihydro)rifamycin S, 4-deoxy-3,4[2-spiro-[1-(3,3-dimethylbutanoyl)-piperidin-4-yl]]-(1H)-imidazo-(2,5-dihydro)rifamycin S, 4-deoxy-3,4[2-spiro[1-(isobutylaminocarbonyl)-piperidin-4-yl]]-(1H)-imidazo-(2,5-dihydro)rifamycin S, 4-deoxy-3,4[2-spiro-[1-(isopropylaminocarbonyl)-piperidin-4-yl]]-(1H)-imidazo-(2,5-dihydro)rifamycin S, 4-deoxy-3,4[2-spiro-[1-((1-methylpropyl) aminocarbonyl)-piperidin-4-yl]]-(1H)-imidazo-(2,5-dihydro)rifamycin S, or 4-deoxy-3,4[2-spiro-[1-(t-butylaminocarbonyl)-piperidin-4-yl]]-(1H)-imidazo-(2,5-dihydro)rifamycin S,. 12. The method of claim 1 , wherein the composition is 4-deoxy-3,4[2-spiro-[1-(isobutyloxycarbonyl)-piperidin-4-yl]]-(1H)-imidazo-(2,5-dihydro)rifamycin S. 13. The method of claim 1 , wherein the parasite is Haemonchus contortus. 14. The method of claim 1 , wherein the antiparasitic drug is ivermectin. 15. The method of claim 1 , wherein the antiparasitic drug is iodoquinol. 16. The method of claim 1 , wherein the antiparasitic drug is chloroquine, primaquine, mefloquine, quinine, or quinidine. 17. The method of claim 1 , wherein the antiparasitic drug is praziquantel, or oxyminquine. 18. The method of claim 1 , wherein the composition is 11-deoxy-11-amino-4-deoxy-3,4[2-spiro-[1-(isobutyloxycarbonyl)-piperidin-4-yl]]-(1H)-imidazo-(2,5-dihydro)rifamycin S.

Assignees

Inventors

Classifications

  • Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

  • Antiparasitic agents · CPC title

  • having six-membered rings with one nitrogen as the only ring hetero atom · CPC title

  • Heterocyclic compounds (A61K47/558 takes precedence) · CPC title

  • Carboxylic acids, e.g. a fatty acid or an amino acid · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10226455B2 cover?
Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof in an amount and formulation sufficient to inhibit or induce drug-sensitization in a parasite. The methods can comprise administering a rifamycin deri…
Who is the assignee on this patent?
Sacchettini James C, Miller Matthew W, Wallis Deeann, and 3 more
What technology area does this patent fall under?
Primary CPC classification A61K31/454. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).